Market Overview:
The global docetaxel anhydrous API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel anticancer drugs, and growing focus on R&D activities by pharmaceutical companies. Based on type, the global docetaxel anhydrous API market is segmented into purity ≥ 95 % and purity ≥ 98 %. The purity ≥ 95 % segment is expected to account for a larger share of the market in 2018 owing to its lower cost as compared to products with higher purities. Based on application, the global docetaxel anhydrous API market is segmented into docetaxel anhydrous injection and other applications. The injection segment accounted for a larger share of the market in 2017 and is projected to grow at a higher CAGR during the forecast period. This can be attributed to rising demand for injectable drugs across regions. Geographically, North America accounted for the largest share of the global docetaxel anhydrous API market in 2017 followed by Europe and Asia Pacific respectively.
Product Definition:
Docetaxel Anhydrous API is a pharmaceutical agent that is used in the treatment of various forms of cancer. It belongs to a class of drugs known as taxanes, and works by inhibiting cell division and tumor growth.
Purity ≥ 95 %:
Docetaxel Anhydrous API is a pure form of taxane, which is extracted from the leaves ofTaxus baccata. Docetaxel has been approved by the U.S. FDA and EMA as a first-line treatment for metastatic breast cancer in combination with an anthracycline antibiotic such as doxorubicin or bleomycin.
Purity ≥ 98 %:
Docetaxel anhydrous is a pure form of taxane, which is used in the treatment of breast cancer and non-small cell lung cancer (NSCLC). Docetaxel has been reported to have better efficacy when compared with the conventional ones. It also shows better results in terms of safety and tolerability.
Application Insights:
Docetaxel anhydrous injection was the largest application segment in 2017 and is expected to maintain its dominance over the forecast period. The drug is used for the treatment of breast, lung, and blood cancers. Breast cancer accounted for a major share in 2017 owing to high usage rates of docetaxel anhydrous injection for this specific purpose coupled with awareness programs conducted by various public and private organizations.
The lung cancer segment is expected to register a significant CAGR during the forecast period due to increasing incidence rates globally coupled with rising awareness about early diagnosis methods. In addition, growing R&D initiatives undertaken by key industry players are also likely to have a positive impact on growth prospects over the next few years.
Regional Analysis:
North America dominated the global docetaxel anhydrous API market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; AbbVie Inc.; and Taxotere Ltd., in this region. North America is also projected to be a prominent regional market over the forecast period owing to various factors such as increasing awareness about cancer treatment options, high disposable income of consumers, and availability of effective treatment methods for various cancers.
Asia Pacific is expected to witness lucrative growth over the forecast period due to rising healthcare expenditure by governments and private sectors coupled with growing patient awareness levels regarding available treatments for different types of cancers. In addition, rapidly developing medical tourism industry in emerging countries like China & India are expected favorably impact regional growth during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the docetaxel anhydrous API market. According to a study by World Health Organization (WHO), it is estimated that around 14 million new cases of cancer were diagnosed in 2012 and this number is expected to rise to 24 million by 2035. This will create a high demand for docetaxel anhydrous API, as it is one of the most commonly used drugs for treatment of various types of cancers.
- Rising awareness about cancer treatments: There has been a rising awareness about different types of cancers and their treatments in recent years. This has led to an increase in the demand for docetaxel anhydrous API, as it is one of the most effective drugs available for treating various types of cancers.
- Technological advancements in chemotherapy: There have been significant advancements made in chemotherapy technology over the past few years, which has led to increased use if docetaxel anhydrous API for treatment purposes across the globe .This will continue to be a key growth driver for this market over next few years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Docetaxel Anhydrous API Market Research Report
By Type
Purity ≥ 95 %, Purity ≥ 98 %
By Application
Docetaxel Anhydrous Injection, Other
By Companies
Phyton Biotech, Scion Pharm Taiwan, Aspen Biopharma Labs, Arca Pharmalabs, Fresenius Kabi Oncology, Dr. Reddy's Laboratories, Fujian South Pharmaceutical, Hainan Yew Pharmaceutical, Hubei Haosun Pharmaceutical, Tecoland, Phyton Biotech, Berr Chemical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Docetaxel Anhydrous API Market Report Segments:
The global Docetaxel Anhydrous API market is segmented on the basis of:
Types
Purity ≥ 95 %, Purity ≥ 98 %
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Docetaxel Anhydrous Injection, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Phyton Biotech
- Scion Pharm Taiwan
- Aspen Biopharma Labs
- Arca Pharmalabs
- Fresenius Kabi Oncology
- Dr. Reddy's Laboratories
- Fujian South Pharmaceutical
- Hainan Yew Pharmaceutical
- Hubei Haosun Pharmaceutical
- Tecoland
- Phyton Biotech
- Berr Chemical
Highlights of The Docetaxel Anhydrous API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥ 95 %
- Purity ≥ 98 %
- By Application:
- Docetaxel Anhydrous Injection
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Docetaxel Anhydrous API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Docetaxel is anhydrous form of the drug taxetaxel. It is a chemotherapy agent used to treat cancer.
Some of the major players in the docetaxel anhydrous api market are Phyton Biotech, Scion Pharm Taiwan, Aspen Biopharma Labs, Arca Pharmalabs, Fresenius Kabi Oncology, Dr. Reddy's Laboratories, Fujian South Pharmaceutical, Hainan Yew Pharmaceutical, Hubei Haosun Pharmaceutical, Tecoland, Phyton Biotech, Berr Chemical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Docetaxel Anhydrous API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Docetaxel Anhydrous API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Docetaxel Anhydrous API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Docetaxel Anhydrous API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Docetaxel Anhydrous API Market Size & Forecast, 2018-2028
4.5.1 Docetaxel Anhydrous API Market Size and Y-o-Y Growth
4.5.2 Docetaxel Anhydrous API Market Absolute $ Opportunity
Chapter 5 Global Docetaxel Anhydrous API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Docetaxel Anhydrous API Market Size Forecast by Type
5.2.1 Purity ≥ 95 %
5.2.2 Purity ≥ 98 %
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Docetaxel Anhydrous API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Docetaxel Anhydrous API Market Size Forecast by Applications
6.2.1 Docetaxel Anhydrous Injection
6.2.2 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Docetaxel Anhydrous API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Docetaxel Anhydrous API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Docetaxel Anhydrous API Analysis and Forecast
9.1 Introduction
9.2 North America Docetaxel Anhydrous API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Docetaxel Anhydrous API Market Size Forecast by Type
9.6.1 Purity ≥ 95 %
9.6.2 Purity ≥ 98 %
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Docetaxel Anhydrous API Market Size Forecast by Applications
9.10.1 Docetaxel Anhydrous Injection
9.10.2 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Docetaxel Anhydrous API Analysis and Forecast
10.1 Introduction
10.2 Europe Docetaxel Anhydrous API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Docetaxel Anhydrous API Market Size Forecast by Type
10.6.1 Purity ≥ 95 %
10.6.2 Purity ≥ 98 %
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Docetaxel Anhydrous API Market Size Forecast by Applications
10.10.1 Docetaxel Anhydrous Injection
10.10.2 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Docetaxel Anhydrous API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Docetaxel Anhydrous API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Docetaxel Anhydrous API Market Size Forecast by Type
11.6.1 Purity ≥ 95 %
11.6.2 Purity ≥ 98 %
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Docetaxel Anhydrous API Market Size Forecast by Applications
11.10.1 Docetaxel Anhydrous Injection
11.10.2 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Docetaxel Anhydrous API Analysis and Forecast
12.1 Introduction
12.2 Latin America Docetaxel Anhydrous API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Docetaxel Anhydrous API Market Size Forecast by Type
12.6.1 Purity ≥ 95 %
12.6.2 Purity ≥ 98 %
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Docetaxel Anhydrous API Market Size Forecast by Applications
12.10.1 Docetaxel Anhydrous Injection
12.10.2 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Docetaxel Anhydrous API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Docetaxel Anhydrous API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Docetaxel Anhydrous API Market Size Forecast by Type
13.6.1 Purity ≥ 95 %
13.6.2 Purity ≥ 98 %
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Docetaxel Anhydrous API Market Size Forecast by Applications
13.10.1 Docetaxel Anhydrous Injection
13.10.2 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Docetaxel Anhydrous API Market: Competitive Dashboard
14.2 Global Docetaxel Anhydrous API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Phyton Biotech
14.3.2 Scion Pharm Taiwan
14.3.3 Aspen Biopharma Labs
14.3.4 Arca Pharmalabs
14.3.5 Fresenius Kabi Oncology
14.3.6 Dr. Reddy's Laboratories
14.3.7 Fujian South Pharmaceutical
14.3.8 Hainan Yew Pharmaceutical
14.3.9 Hubei Haosun Pharmaceutical
14.3.10 Tecoland
14.3.11 Phyton Biotech
14.3.12 Berr Chemical
